96 Kensington High Street
36 articles with MiNA Therapeutics
Eli Lilly and Company and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, announced a global research collaboration to develop novel drug candidates using MiNA's proprietary small activating RNA technology platform.
Eli Lilly announced a drug development collaboration with MiNA Therapeutics Limited focusing on five novel drug candidates that could be worth up to $245 million.
MiNA Therapeutics Presents Translational Data at AACR Supporting MTL-CEBPA as Immunological Cancer Combination Treatment
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced translational data supporting the favourable immunological effects of MTL-CEBPA and its benefits in combination with other cancer therapies including anti-PD1 checkpoint inhibition.
Data on multiple oncology therapeutic programs are being unveiled ahead of the start of the annual American Association for Cancer Research meeting, which will be held virtually this year due to the ongoing COVID-19 pandemic.
MiNA eligible for up to 220 M€ in upfront, development and commercial milestone payments for first target.
Servier and MiNA Therapeutics are partnering on small activating RNA (saRNA) therapies to treat neurological diseases. saRNA is an entirely new class of drugs.
1/8/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced the appointment of Robin Wright as Chief Financial Officer, effective January 04, 2021.
10/2/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced the appointment of Peter Bains as Chief Business Officer, effective September 22, 2020.
The financing will be used by MiNA to advance the company’s pipeline of proprietary, first-in-class, small activating RNA therapeutics.
MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics
Funding, led by aMoon, will advance the clinical development of MiNA’s new class of RNA therapeutics for cancer treatment, and further expand its R&D pipeline in additional disease areas
MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL‑CEBPA in Combination with Sorafenib in Liver Cancer at 2020 ASCO Annual Meeting
Observed clinical activity, including durable and complete tumour responses, suggests that MTL‑CEBPA may increase the effectiveness of sorafenib standard of care
5/28/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
MiNA Therapeutics Announces Publication of Phase I Liver Cancer Data in Clinical Cancer Research and Provides Update on Clinical Development and Drug Discovery Programs
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced the publication of data from its Phase I liver cancer trial, OUTREACH, in Clinical Cancer Research.
3/5/2020Life sciences companies from across the globe provide updates on their businesses and pipelines.
MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL‑CEBPA in Combination with anti-PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumours
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced the initiation and first patient treated in TIMEPOINT, a global Phase 1/1b clinical study of MTL-CEBPA in combination with anti-PD1 checkpoint inhibitor pembrolizumab in patients with advanced solid tumours.
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced the initiation of a research collaboration with AstraZeneca to evaluate small activating RNA molecules in metabolic diseases.
MiNA said the collaboration will combine its “expertise in the discovery and development of saRNA therapeutics” with AstraZeneca’s experience in “identifying and bringing breakthrough treatments to patients with metabolic diseases.”
MiNA Therapeutics Presents Clinical and Pre-Clinical Data at ESMO Supporting MTL-CEBPA as Immunological Combination Treatment
Final results from Phase 1 study of MTL-CEBPA in advanced liver cancer patients demonstrate clinical activity and attractive safety profile